MCID: PNC013
MIFTS: 48

Pancreatic Ductal Carcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Carcinoma

MalaCards integrated aliases for Pancreatic Ductal Carcinoma:

Name: Pancreatic Ductal Carcinoma 12 15
Carcinoma, Pancreatic Ductal 44 73
Malignant Neoplasm of Duct of Wirsung 12
Carcinoma Pancreatic Ductal 55
Pancreatic Duct Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3587
ICD10 33 C25.3
ICD9CM 35 157.3
MeSH 44 D021441
SNOMED-CT 68 187793004 93939009

Summaries for Pancreatic Ductal Carcinoma

Disease Ontology : 12 A pancreatic carcinoma located in the pancreatic duct.

MalaCards based summary : Pancreatic Ductal Carcinoma, also known as carcinoma, pancreatic ductal, is related to microcystic adenoma and cystadenocarcinoma. An important gene associated with Pancreatic Ductal Carcinoma is MUC6 (Mucin 6, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Pathways in cancer and Gastric cancer. The drugs Gemcitabine and Axitinib have been mentioned in the context of this disorder. Affiliated tissues include the pancreatic duct, pancreas and endothelial, and related phenotypes are cellular and cardiovascular system

Related Diseases for Pancreatic Ductal Carcinoma

Diseases related to Pancreatic Ductal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 235)
# Related Disease Score Top Affiliating Genes
1 microcystic adenoma 31.0 MUC1 MUC6
2 cystadenocarcinoma 29.1 KRT7 MUC1 MUC2 TP53 VEGFA
3 adenocarcinoma 27.8 CDKN2A MUC1 SMAD4 TP53 VEGFA
4 pancreatic cancer 27.2 CDKN2A MUC1 MUC2 SMAD4 TP53 VEGFA
5 adenosquamous pancreas carcinoma 11.1
6 solid adenocarcinoma with mucin production 10.9 KRT7 MUC1
7 endosalpingiosis 10.9 KRT7 MUC1
8 parachordoma 10.9 KRT7 MUC1
9 middle ear adenoma 10.9 KRT7 MUC1
10 malignant mixed mullerian tumor 10.8 KRT7 MUC1
11 nodular hidradenoma 10.8 KRT7 MUC1
12 apocrine adenocarcinoma 10.8 KRT7 MUC1
13 monophasic synovial sarcoma 10.8 KRT7 MUC1
14 mucinous intrahepatic cholangiocarcinoma 10.8 MUC2 MUC6
15 nephrogenic adenoma 10.8 KRT7 MUC1
16 mucinous ovarian cystadenoma 10.8 KRT7 MUC1
17 cystic basal cell carcinoma 10.8 KRT20 KRT7
18 vaginal benign neoplasm 10.8 KRT20 KRT7
19 seminal vesicle adenocarcinoma 10.8 KRT20 KRT7
20 pancreatic serous cystadenoma 10.8 KRT7 VEGFA
21 transverse colon cancer 10.8 KRT20 KRT7
22 appendix adenocarcinoma 10.8 KRT20 KRT7
23 ovarian large-cell neuroendocrine carcinoma 10.8 KRT20 KRT7
24 vaginal adenoma 10.8 KRT20 KRT7
25 vaginal tubulovillous adenoma 10.8 KRT20 KRT7
26 eyelid neoplasm 10.8 KRT20 KRT7
27 glandular cystitis 10.7 KRT20 KRT7
28 pancreatitis 10.7
29 malignant syringoma 10.7 KRT20 KRT7
30 krukenberg carcinoma 10.7 KRT20 KRT7
31 large intestine adenocarcinoma 10.7 KRT20 KRT7
32 linitis plastica 10.7 KRT20 KRT7
33 hidradenoma 10.7 KRT7 MUC1
34 lung acinar adenocarcinoma 10.7 KRT20 KRT7
35 small cell carcinoma of the bladder 10.7 KRT20 KRT7
36 adenoid squamous cell carcinoma 10.7 KRT20 KRT7
37 sertoli-leydig cell tumor 10.7 KRT7 MUC1
38 intratubular embryonal carcinoma 10.7 KRT20 KRT7
39 thymus adenocarcinoma 10.7 KRT20 KRT7
40 gastric diffuse adenocarcinoma 10.7 KRT20 KRT7
41 meibomian cyst 10.7 KRT20 KRT7
42 bladder lymphoma 10.7 KRT20 KRT7
43 bladder adenocarcinoma 10.7 KRT20 KRT7
44 jejunal adenocarcinoma 10.7 KRT20 KRT7
45 chronic cystitis 10.7 KRT20 KRT7
46 malignant spiradenoma 10.7 KRT7 TP53
47 medulloepithelioma 10.6 KRT20 KRT7
48 female reproductive endometrioid cancer 10.6 KRT7 TP53
49 villous adenoma 10.6 KRT20 MUC1
50 chordoid glioma 10.6 MUC1 TP53

Graphical network of the top 20 diseases related to Pancreatic Ductal Carcinoma:



Diseases related to Pancreatic Ductal Carcinoma

Symptoms & Phenotypes for Pancreatic Ductal Carcinoma

MGI Mouse Phenotypes related to Pancreatic Ductal Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.97 CDKN2A DNM2 KRT7 MUC2 SMAD4 TGM2
2 cardiovascular system MP:0005385 9.91 CDKN2A DNM2 MUC2 SMAD4 TGM2 TP53
3 homeostasis/metabolism MP:0005376 9.81 CDKN2A DNM2 KRT7 MUC2 SMAD4 TGM2
4 digestive/alimentary MP:0005381 9.73 CDKN2A DNM2 MUC2 SMAD4 TP53 VEGFA
5 neoplasm MP:0002006 9.43 CDKN2A MUC2 SMAD4 TGM2 TP53 VEGFA
6 renal/urinary system MP:0005367 9.1 DNM2 KRT7 SMAD4 TGM2 TP53 VEGFA

Drugs & Therapeutics for Pancreatic Ductal Carcinoma

Drugs for Pancreatic Ductal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 65)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
2
Axitinib Approved, Investigational Phase 3 319460-85-0 6450551
3
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
4
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
5 Anti-Infective Agents Phase 3,Phase 2,Phase 1
6 Antimetabolites Phase 3,Phase 2,Phase 1
7 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
8 Antiviral Agents Phase 3,Phase 2,Phase 1
9 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
10 Protein Kinase Inhibitors Phase 3
11 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
12 Antimitotic Agents Phase 3,Phase 2,Phase 1
13 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
14 acivicin Phase 3
15 Adjuvants, Immunologic Phase 3
16 Protective Agents Phase 3,Phase 1
17 Viscosupplements Phase 3
18
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
19
Pancrelipase Approved, Investigational Phase 2,Phase 1,Not Applicable 53608-75-6
20
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
21
Fluorouracil Approved Phase 2,Phase 1 51-21-8 3385
22
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
23
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
24
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
25
Doxil Approved June 1999 Phase 2 31703
26
Tremelimumab Investigational Phase 2,Phase 1 745013-59-6
27
Camptothecin Experimental Phase 2 7689-03-4
28
Apaziquone Investigational Phase 1, Phase 2 114560-48-4 5813717
29
Erlotinib Hydrochloride Phase 2 183319-69-9 176871
30 pancreatin Phase 2,Phase 1,Not Applicable
31 Anti-Bacterial Agents Phase 2
32 Antibiotics, Antitubercular Phase 2
33 Topoisomerase Inhibitors Phase 2,Phase 1
34 Antibodies Phase 2,Phase 1,Early Phase 1
35 Antibodies, Monoclonal Phase 2,Phase 1,Early Phase 1
36 Immunoglobulins Phase 2,Phase 1,Early Phase 1
37
s 1 (combination) Phase 2
38 topoisomerase I inhibitors Phase 2,Phase 1
39 Cola Nutraceutical Phase 1, Phase 2
40
Azacitidine Approved, Investigational Phase 1 320-67-2 9444
41
Carboplatin Approved Phase 1 41575-94-4 10339178 498142 38904
42
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
43
Etoposide Approved Phase 1 33419-42-0 36462
44
Levoleucovorin Approved, Investigational Phase 1 68538-85-2
45
Folic Acid Approved, Nutraceutical, Vet_approved Phase 1 59-30-3 6037
46 Antidotes Phase 1
47 Calcium, Dietary Phase 1
48 Etoposide phosphate Phase 1
49 Hematinics Phase 1
50 Micronutrients Phase 1

Interventional clinical trials:

(show all 35)
# Name Status NCT ID Phase Drugs
1 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. Completed NCT00471146 Phase 3 AG-013736;Gemcitabine;Gemcitabine;placebo
2 A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenoca Recruiting NCT02715804 Phase 3 Placebo;Nab-paclitaxel;Gemcitabine
3 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
4 Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer Unknown status NCT01394120 Phase 2 Targeted Therapy Tailored Treatment;Standard Chemotherapy
5 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer Completed NCT01580397 Phase 2 INNO-206
6 Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Completed NCT02558894 Phase 2 MEDI4736 monotherapy;tremelimumab+MEDI4736
7 QUILT-3.019: Phase 2 Study of NPC-1C Chimeric Monoclonal Antibody to Treat Pancreatic and Colorectal Cancer Completed NCT01040000 Phase 1, Phase 2 NPC-1C/NEO-102
8 Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer Completed NCT00226746 Phase 2 Paclitaxel and gemcitabine
9 Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) Completed NCT01808638 Phase 1, Phase 2 Atu027 & gemcitabine in lead in safety period;Atu027 & gemcitabine in treatment arm 1;Atu027 & gemcitabine in treatment arm 2
10 A Study of AGS-1C4D4 in Pancreatic Cancer Subjects Previously Treated in Protocol 2008002 Completed NCT01608711 Phase 2
11 A Study of AGS-1C4D4 Given in Combination With Gemcitabine in Subjects With Metastatic Pancreatic Cancer Completed NCT00902291 Phase 2
12 Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer Recruiting NCT02529579 Phase 1, Phase 2 Gemcitabine
13 The Combination Chemotherapy of SIRIOX as First‑Line Chemotherapy for Pancreatic Cancer Recruiting NCT03403101 Phase 2 S1;Oxaliplatin;Irinotecan
14 Parvovirus H-1 (ParvOryx) in Patients With Metastatic Inoperable Pancreatic Cancer Recruiting NCT02653313 Phase 1, Phase 2 Parvovirus H-1 (H-1PV)
15 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Active, not recruiting NCT02583477 Phase 1, Phase 2 MEDI4736 in combination with nab-paclitaxel and gemcitabine;MEDI4736 in combination with AZD5069
16 PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Subjects With Stage IV Untreated Pancreatic Cancer Active, not recruiting NCT01839487 Phase 2 PEGPH20+nab-paclitaxel+gemcitabine;nab-paclitaxel + gemcitabine
17 Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer Terminated NCT02243007 Phase 2 FOLFIRINOX;Gemcitabine/nab-Paclitaxel;Capecitabine
18 A Dose-Finding Study of OTX105/MK-8628, a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) Completed NCT02259114 Phase 1 OTX015/MK-8628
19 A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Completed NCT01478685 Phase 1 CC-486;Carboplatin;ABI-007
20 Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Recruiting NCT02658214 Phase 1 paclitaxel + carboplatin;carboplatin + etoposide;gemcitabine + carboplatin;nab-paclitaxel (paclitaxel-albumin) + carboplatin;oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid);nab-paclitaxel (paclitaxel-albumin) + gemcitabine;cisplatin + 5-fluorouracil (5FU)
21 A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer Active, not recruiting NCT02231723 Phase 1 BBI608;Nab-paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Irinotecan;Fluorouracil;MM-398
22 According CTC to Compare the Influences of Different Methods to Remove the PDAC Unknown status NCT02451384 Not Applicable
23 An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy Unknown status NCT02310230 Not Applicable
24 Circulating Tumor Cells in Operative Blood Completed NCT02150746
25 Clinical Trial of Pancreatic Cancer in Stockholm. Completed NCT02162823
26 Continuous Monitoring on the General Ward Completed NCT02933307 Not Applicable
27 CT Pancreas Perfusion Completed NCT00588367
28 Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma Recruiting NCT02928081 Not Applicable
29 Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection Recruiting NCT02750657
30 Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1) Recruiting NCT03513705 Not Applicable
31 Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study. Recruiting NCT03500068 Not Applicable
32 Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas Recruiting NCT02817308 Not Applicable
33 Detection of MicroRNA-25 in the Diagnosis of Pancreatic Cancer Not yet recruiting NCT03432624
34 Amatuximab for High Mesothelin Cancers Terminated NCT01413451 Early Phase 1 Amatuximab (MORab-009)
35 Pancreatic Cancer Can be Detected by Adrenomedullin in New Onset Diabetes Patients Terminated NCT02456051

Search NIH Clinical Center for Pancreatic Ductal Carcinoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: carcinoma, pancreatic ductal

Genetic Tests for Pancreatic Ductal Carcinoma

Anatomical Context for Pancreatic Ductal Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Pancreatic Ductal Carcinoma:

19
The Pancreatic Duct

MalaCards organs/tissues related to Pancreatic Ductal Carcinoma:

41
Pancreas, Endothelial, T Cells, Liver, Bone, Bone Marrow

Publications for Pancreatic Ductal Carcinoma

Articles related to Pancreatic Ductal Carcinoma:

(show top 50) (show all 84)
# Title Authors Year
1
Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report. ( 29409514 )
2018
2
The Clinical Significance of miR-34a in Pancreatic Ductal Carcinoma and Associated Molecular and Cellular Mechanisms. ( 27458977 )
2017
3
Immunohistochemical Antibody Panel for the Differential Diagnosis of Pancreatic Ductal Carcinoma From Gastrointestinal Contamination and Benign Pancreatic Duct Epithelium in Endoscopic Ultrasound-Guided Fine-Needle Aspiration. ( 28099249 )
2017
4
Adjuvant treatment for pancreatic ductal carcinoma. ( 28639051 )
2017
5
Worsened outcome in patients with pancreatic ductal carcinoma on long-term diabetes: association with E-cadherin1 (CDH1) promoter methylation. ( 29273724 )
2017
6
Plasma membrane expression of ZNF185 is a prognostic factor in pancreatic ductal carcinoma. ( 28927124 )
2017
7
Functions of pancreatic stellate cell-derived soluble factors in the microenvironment of pancreatic ductal carcinoma. ( 29254283 )
2017
8
Insulin resistance is associated with the aggressiveness of pancreatic ductal carcinoma. ( 27552832 )
2016
9
Efficacy of contrast-enhanced harmonic endoscopic ultrasonography in the diagnosis of pancreatic ductal carcinoma. ( 27184637 )
2016
10
A case report on metastatic pancreatic tumor from pulmonary adenocarcinoma that difficult to differentiate from primary pancreatic ductal carcinoma. ( 27498937 )
2016
11
Second primary pancreatic ductal carcinoma in the remnant pancreas after pancreatectomy for pancreatic ductal carcinoma: High cumulative incidence rates at 5 years after pancreatectomy. ( 27237099 )
2016
12
Alternative splicing of NUMB, APP and VEGFA as the features of pancreatic ductal carcinoma. ( 26261495 )
2015
13
Clinicopathological Significance of ASC-Amino Acid Transporter 2 (ASCT2) Expression in Pancreatic Ductal Carcinoma. ( 24845232 )
2014
14
Alteration of strain ratio evaluated by transabdominal ultrasound elastography may predict the efficacy of preoperative chemoradiation performed for pancreatic ductal carcinoma: preliminary results. ( 24901166 )
2014
15
Successful management of metachronous liver metastasis after pancreaticoduodectomy for pancreatic ductal carcinoma using hepatectomy and chemotherapy: a case report. ( 24778053 )
2014
16
Pancreatic intraglandular metastasis predicts poorer outcome in postoperative patients with pancreatic ductal carcinoma. ( 23648465 )
2013
17
Clinicopathologic assessment of pancreatic ductal carcinoma located at the head of the pancreas, in relation to embryonic development. ( 22228049 )
2012
18
Nm23/nucleoside diphosphate kinase-A as a potent prognostic marker in invasive pancreatic ductal carcinoma identified by proteomic analysis of laser micro-dissected formalin-fixed paraffin-embedded tissue. ( 22892044 )
2012
19
Preoperative platelet-lymphocyte ratio in resected pancreatic ductal carcinoma: is it meaningful? ( 20579970 )
2012
20
Increased expression of the large GTPase dynamin 2 potentiates metastatic migration and invasion of pancreatic ductal carcinoma. ( 21841817 )
2012
21
Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model. ( 22190076 )
2012
22
Assessment of the interface between retroperitoneal fat infiltration of pancreatic ductal carcinoma and the major artery by multidetector-row computed tomography: surgical outcomes and correlation with histopathological extension. ( 22562451 )
2012
23
KLF4 is a novel candidate tumor suppressor gene in pancreatic ductal carcinoma. ( 21224073 )
2011
24
Cytologic features of pancreatic intraepithelial neoplasia and pancreatitis: potential pitfalls in the diagnosis of pancreatic ductal carcinoma. ( 20730891 )
2011
25
Expression of KL-6/MUC1 in pancreatic ductal carcinoma and its potential relationship with I^-catenin in tumor progression. ( 21466814 )
2011
26
Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1. ( 21272935 )
2011
27
Asymptomatic curable pancreatic ductal carcinoma detected during the follow-up of pancreatic cysts distinct from carcinoma. ( 26190721 )
2011
28
Combination of MUC5ac and WT-1 immunohistochemistry is useful in distinguishing pancreatic ductal carcinoma from ovarian serous carcinoma in effusion cytology. ( 19856421 )
2010
29
Does contrast-enhanced ultrasound reveal tumor angiogenesis in pancreatic ductal carcinoma? A prospective study. ( 18845377 )
2009
30
Correlations between p53 gene mutations and histologic characteristics of pancreatic ductal carcinoma. ( 19248224 )
2009
31
Secretion of N-ERC/mesothelin and expression of C-ERC/mesothelin in human pancreatic ductal carcinoma. ( 19020717 )
2008
32
Expression of EGF and EGFR strongly correlates with metastasis of pancreatic ductal carcinoma. ( 18505086 )
2008
33
Expression of matrix metalloproteinase 9 in pancreatic ductal carcinoma is associated with tumor metastasis formation. ( 17378244 )
2007
34
Reappraisal of the clinical significance of tumor size in patients with pancreatic ductal carcinoma. ( 17003643 )
2006
35
Pancreatic ductal carcinoma: from the bench to the bedside. ( 16998251 )
2006
36
Strong prognostic value of nodal and bone marrow micro-involvement in patients with pancreatic ductal carcinoma receiving no adjuvant chemotherapy. ( 17072983 )
2006
37
Retroviral expression screening of oncogenes in pancreatic ductal carcinoma. ( 16125925 )
2005
38
Experimental trial for diagnosis of pancreatic ductal carcinoma based on gene expression profiles of pancreatic ductal cells. ( 16053509 )
2005
39
Evaluation of vascular signal in pancreatic ductal carcinoma using contrast enhanced ultrasonography: effect of systemic chemotherapy. ( 15951559 )
2005
40
Proteomic analysis of pancreatic ductal carcinoma cells after combined treatment with gemcitabine and trichostatin A. ( 16335935 )
2005
41
Intercalated duct cell is starting point in development of pancreatic ductal carcinoma? ( 16018800 )
2005
42
Factors predicting recurrence after resection of pancreatic ductal carcinoma. ( 15968250 )
2005
43
Alterations of tumor suppressor gene p16INK4a in pancreatic ductal carcinoma. ( 15985168 )
2005
44
Detection of tumor cell dissemination in pancreatic ductal carcinoma patients by CK 20 RT-PCR indicates poor survival. ( 16136352 )
2005
45
Evaluation of blood flow in pancreatic ductal carcinoma using contrast-enhanced, wide-band Doppler ultrasonography: correlation with tumor characteristics and vascular endothelial growth factor. ( 15084983 )
2004
46
Microarray-based gene expression profiling in pancreatic ductal carcinoma: status quo and perspectives. ( 14745573 )
2004
47
A comprehensive in vitro characterization of pancreatic ductal carcinoma cell line biological behavior and its correlation with the structural and genetic profile. ( 15258755 )
2004
48
Terminally modified oligodeoxynucleotides directed against p53 in an orthotopic xenograft model: a novel adjuvant treatment strategy for pancreatic ductal carcinoma. ( 14707723 )
2004
49
Tumor stroma interactions induce chemoresistance in pancreatic ductal carcinoma cells involving increased secretion and paracrine effects of nitric oxide and interleukin-1beta. ( 14973050 )
2004
50
Gene expression profiling of microdissected pancreatic ductal carcinomas using high-density DNA microarrays. ( 15548371 )
2004

Variations for Pancreatic Ductal Carcinoma

Expression for Pancreatic Ductal Carcinoma

Search GEO for disease gene expression data for Pancreatic Ductal Carcinoma.

Pathways for Pancreatic Ductal Carcinoma

Pathways related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Super pathways Score Top Affiliating Genes
1 12.6 CDKN2A SMAD4 TP53 VEGFA
2
Show member pathways
12.52 CDKN2A MUC2 SMAD4 TP53
3 12.11 DNM2 KRT20 KRT7 MUC1
4
Show member pathways
12.01 MUC1 MUC2 MUC6
5 11.95 SMAD4 TP53 VEGFA
6 11.87 SMAD4 TP53 VEGFA
7
Show member pathways
11.82 MUC1 MUC2 MUC6
8 11.69 CDKN2A SMAD4 TP53
9 11.67 MUC1 TP53 VEGFA
10
Show member pathways
11.62 MUC1 MUC2 MUC6
11 11.57 CDKN2A SMAD4 TP53
12 11.34 CDKN2A SMAD4 TP53 VEGFA
13 11.17 CDKN2A TP53 VEGFA
14 11.04 SMAD4 TP53 VEGFA
15 10.88 CDKN2A TP53
16
Show member pathways
10.87 CDKN2A TP53
17 10.82 MUC2 SMAD4
18 10.79 CDKN2A TP53 TYMP VEGFA

GO Terms for Pancreatic Ductal Carcinoma

Cellular components related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.8 MUC1 MUC2 MUC6

Biological processes related to Pancreatic Ductal Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.56 CDKN2A DNM2 TGM2 TP53
2 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.54 MUC1 MUC2 MUC6
3 negative regulation of cell growth GO:0030308 9.5 CDKN2A SMAD4 TP53
4 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.4 MUC1 TP53
5 replicative senescence GO:0090399 9.16 CDKN2A TP53
6 maintenance of gastrointestinal epithelium GO:0030277 8.96 MUC2 MUC6
7 O-glycan processing GO:0016266 8.8 MUC1 MUC2 MUC6

Sources for Pancreatic Ductal Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....